The landscape of endocrine medicine underwent a significant transformation this month as the U.S. Food and Drug Administration (FDA) issued a landmark approval for the first once-weekly basal insulin, while a sophisticated new artificial intelligence platform launched to tackle the diagnostic complexities of chronic metabolic disease. Simultaneously, progress in the rare disease sector continues as clinical trial data for congenital hyperinsulinism undergoes rigorous regulatory review. These developments signal a broader shift toward precision medicine and patient-centric treatment modalities that aim to reduce the daily burden of chronic disease management.
Awiqli: A Paradigm Shift in Basal Insulin Therapy
On March 26, the FDA officially granted approval to Novo Nordisk’s Awiqli (insulin icodec-abae) injection 700 units/mL. This decision marks the introduction of the first and only once-weekly, long-acting basal insulin available in the United States. Indicated as an adjunct to diet and exercise, Awiqli is designed to improve glycemic control in adults living with type 2 diabetes.
For decades, the standard of care for basal insulin therapy has required daily subcutaneous injections. While effective, the requirement for 365 injections per year often leads to "injection fatigue," reduced compliance, and clinical inertia, where both patients and providers delay the initiation of insulin due to the perceived lifestyle burden. The approval of Awiqli reduces the injection frequency from 360-plus days a year to just 52, representing a 85% reduction in the total number of basal insulin administrations.
Clinical Foundation: The ONWARDS Phase 3a Program
The FDA’s decision was underpinned by data from the ONWARDS clinical trial program, a comprehensive suite of six Phase 3a global clinical trials involving more than 4,000 adults with type 1 or type 2 diabetes. For the specific indication of type 2 diabetes, the approval relied on four randomized, active-controlled, treat-to-target trials involving approximately 2,680 participants.
In these trials, Awiqli was evaluated against daily basal insulins, such as insulin glargine U100 and insulin degludec. The primary endpoint across the program was the reduction of HbA1c (A1C), a key indicator of long-term blood sugar management. The results demonstrated that once-weekly Awiqli was non-inferior—and in some trials, superior—to daily basal insulins in lowering A1C levels.
"Awiqli is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes," stated Anna Windle, PhD, Group Vice President of Clinical Development, Medical & Regulatory Affairs at Novo Nordisk Inc. "It’s helping to reframe what basal insulin care can look like by addressing challenges associated with the frequency of daily injections."
Safety and Pharmacological Profile
Awiqli’s safety profile was found to be consistent with the established class of daily basal insulins. The most common adverse event reported was hypoglycemia (low blood sugar). Other noted side effects included injection site reactions, lipodystrophy (skin thickening or pitting), weight gain, and peripheral edema (swelling of hands and feet).
The pharmacological innovation of Awiqli lies in its ability to bind reversibly to albumin, creating a circulating reservoir that releases the insulin slowly and steadily over a seven-day period. This long half-life ensures a consistent glucose-lowering effect throughout the week, mitigating the peaks and troughs sometimes associated with shorter-acting formulations.
Diadia Health: AI Causal Reasoning Enters the Clinical Space
While Novo Nordisk addresses treatment frequency, Diadia Health is focusing on the diagnostic "black box" of endocrine and chronic diseases. On March 19, the company announced its official exit from beta testing, launching the first AI causal reasoning platform designed for precision medicine.
The platform enters a healthcare environment where an estimated 25 to 30 million Americans live with rare or complex chronic diseases that often take years to diagnose. Diadia’s technology is specifically tailored for cases where standard laboratory results appear "normal," yet patients continue to experience debilitating symptoms—a common occurrence in thyroid disorders, adrenal fatigue, and complex metabolic syndromes.
Beyond Large Language Models
Unlike common AI tools based on Large Language Models (LLMs), which have been criticized for "hallucinations" or generating plausible but factually incorrect medical data, Diadia utilizes a causal reasoning engine. This system analyzes patterns across nearly one million genetic variants, 100 metabolic pathways, and hundreds of biomarkers simultaneously.
The platform functions as a vendor-agnostic intelligence layer that integrates with existing lab data. During its beta phase across 12 clinical sites, the platform reportedly helped clinicians identify root causes with 60% less trial-and-error than traditional protocols. Furthermore, 98% of the AI-generated reports were used by physicians without requiring revisions, suggesting a high level of clinical accuracy and trust.
Dr. Anil Bajnath, MD, founder of the American Board of Precision Medicine, highlighted the necessity of such tools: "Precision medicine will be AI-first because of large data volumes. There’s no way a single physician could streamline all that information. Diadia is a non-hallucinating, evidence-driven AI copilot."
The Science of Genetic Expression
A unique feature of the Diadia platform is its ability to distinguish between genetic predisposition and active gene expression. By mapping the biological relationships between genomics and current biomarkers, the platform provides a transparent logic trail for every recommendation, supported by citations from over 310,000 peer-reviewed research papers.
The company, backed by Salesforce Ventures and Sound Ventures, was founded by Dr. Ikonomovska, an AI veteran with experience at Reddit and Google. Her personal struggle with unexplained symptoms despite normal labs served as the catalyst for the platform’s development. The national rollout aims to provide clinicians with a tool that bridges the gap between raw data and actionable, personalized treatment protocols.
Rezolute: Navigating Regulatory Pathways for Rare Diseases
In the realm of rare pediatric and endocrine disorders, Rezolute, Inc. provided a critical update on March 24 regarding its ersodetug (formerly RZ358) program for congenital hyperinsulinism (HI). Following a "Type B" meeting with the FDA on March 17, the company discussed the path forward for its Phase 3 sunRIZE study.
Congenital hyperinsulinism is a rare genetic disorder characterized by the excessive secretion of insulin, leading to frequent and severe episodes of hypoglycemia. If left untreated, the condition can result in permanent brain damage or death in infants and children. Current treatment options are often invasive or carry significant side effects, leaving a high unmet medical need.
Addressing the "Study Effect" in Clinical Trials
The sunRIZE study, a multicenter, double-blind, randomized, placebo-controlled trial, recently faced a setback when it failed to meet its primary endpoint of statistically significant reductions in hypoglycemia compared to a placebo. However, Rezolute maintains that the data remains clinically significant.
The company presented evidence to the FDA suggesting that the primary endpoint was confounded by "behavioral factors." In clinical trials for hypoglycemia, patients and caregivers are often hyper-vigilant, monitoring blood glucose more frequently than they would in a real-world setting. This increased attention can lead to a pronounced "study effect" or placebo response that masks the actual efficacy of the drug.
Despite missing the primary endpoint, the study showed:
- Consistent improvements in "time in hypoglycemia" as measured by Continuous Glucose Monitoring (CGM).
- Evidence of pharmacologic activity with target drug concentrations achieved.
- Favorable observations from an ongoing open-label extension (OLE) showing continued improvement.
The FDA’s Response and Future Outlook
The FDA acknowledged the inherent challenges of measuring hypoglycemia in a heterogeneous patient population like those with HI. The agency specifically noted the limitations of self-monitored blood glucose (SMBG) metrics in these trials.
Rather than dismissing the study, the FDA encouraged Rezolute to submit full study reports and datasets for independent evaluation. This suggests a regulatory willingness to look beyond a single failed endpoint toward the totality of the clinical evidence—a common trend in rare disease regulation where patient populations are small and data is difficult to aggregate.
"We are extremely encouraged by the outcome of our meeting," said Nevan Charles Elam, CEO and Founder of Rezolute. "The agency did not dismiss sunRIZE outright. They expressed a desire to conduct a thorough review that would assist in decision making regarding advancement of the program."
Rezolute expects to provide a further update on the program’s trajectory in the second half of 2026, following the FDA’s independent review of the data.
Broader Implications for Endocrine Health
The simultaneous advancement of once-weekly insulin, AI-driven diagnostics, and rare disease therapeutics reflects a maturing of the endocrine field. The common thread across these three developments is the movement away from "one-size-fits-all" medicine toward a model that prioritizes individual patient biology and lifestyle.
The approval of Awiqli is expected to intensify competition in the basal insulin market, particularly as Eli Lilly develops its own weekly insulin candidate, efsitora alfa. For patients, this competition likely means more choices and better access to long-acting therapies.
In the diagnostic space, the launch of Diadia Health signifies the transition of AI from a theoretical tool to a practical clinical necessity. As the volume of genomic and proteomic data grows, the ability of clinicians to synthesize this information without digital assistance will become increasingly limited.
Finally, the ongoing dialogue between Rezolute and the FDA underscores the complexities of drug development for rare diseases. It highlights the importance of real-world evidence, such as CGM data, in supplementing traditional clinical trial endpoints. Together, these milestones suggest a future where endocrine care is more precise, less burdensome, and increasingly guided by sophisticated data analysis.